Solberg and colleagues proposed the use of G007-LK at low dosage with the PI3K (BKM120) and the epidermal growth factor receptor (EGFR) (erlotinib) inhibitors to treat colon cancer. Here, EGFR is linked to malignant colon neoplasm.